All articles tagged with #overdiagnosis
Pre-biopsy MRI is transforming prostate cancer detection by guiding targeted biopsies and potentially reducing overdiagnosis and biopsy-related complications, but US adoption lags Europe and experts remain split on MRI-targeted biopsy alone versus combining it with systematic biopsies, due to training gaps, access disparities, and financial incentives.
The piece examines neuroscientist Andrew Huberman’s endorsement of whole-body MRIs amid clinician pushback: while proponents say such scans can catch problems early, critics highlight high costs, a high rate of incidental findings, and limited evidence that these scans improve outcomes. Experts warn many findings are not actionable, risking overdiagnosis and resource strain, and that the tests are not a proven, evidence-based tool for asymptomatic individuals.
Elective whole-body MRI screenings are climbing in popularity driven by social media, with proponents arguing for early cancer and condition detection. Medical experts caution these scans often do not improve survival, can lead to unnecessary testing and surgeries from false positives, and come with substantial out-of-pocket costs (about $1,500–$4,000) that insurers rarely cover. Physicians urge weighing benefits against risks and discussing personal history with a primary care provider before deciding.
A Fox News Health piece weighs the pros and cons of whole-body imaging (MRI/CT/PET) for asymptomatic people: scans can potentially detect cancers and other conditions early, but are costly, not routinely covered by insurance, and carry risks of false positives, incidental findings, and overdiagnosis; major medical groups and the FDA warn against routine screening in healthy individuals, though providers cite ongoing research and potential targeted use under physician guidance.
A health explainer warns that more testing isn’t always better: essential screenings like blood sugar and blood pressure can prevent disease, but direct-to-consumer tests and whole-body MRIs often yield incidental findings that lead to costly, unnecessary follow-up and anxiety. Clinicians should guide testing with evidence-based, life-stage recommendations, and readers are urged to question whether a test reduces mortality or just increases diagnoses. In the meantime, focusing on proven basics—healthy lifestyle, regular care, and meaningful activities—remains the best path to health.
A large Cochrane review of six PSA screening trials (nearly 800,000 men) finds PSA testing can reduce prostate cancer deaths, but the absolute benefit is small (about 2 lives saved per 1,000 screened; 500 men need screening to prevent one death). Benefits emerge only with long follow-up, while many men face overdiagnosis and potential harms from treatment, such as incontinence or erectile dysfunction. The authors caution against universal screening and emphasize shared decision making, with targeted approaches for high-risk groups and ongoing development of MRI- and biomarker–based methods whose extra benefit remains uncertain.
A UK analysis of over 400,000 men finds PSA-based prostate cancer screening has low overdiagnosis risk in men in their 50s–60s but rises sharply after 70 due to higher competing mortality; 16% of PSA-detected cancers would not become clinically relevant within 15 years at age 50, rising to 32% at 70 and 58% at 80. Consequently, screening offers little net benefit for men over 70, though MRI-guided biopsy and ongoing trials may reduce harms from overdiagnosis; decisions should be individualized, especially for older men.
Australian researchers show that PSMA PET/CT scans light up aggressive prostate cancers so clearly that many patients with inconclusive MRI can avoid invasive biopsies, potentially halving biopsy rates without missing clinically significant disease; the Primary2 trial (about 660 men) found that those with negative scans did not need biopsies and those with positive scans had targeted biopsies, with two-year follow-up and increasing availability in Australia and Europe.
The piece argues that rising mental-health diagnoses cannot be attributed to overdiagnosis alone; while self-diagnosis and casual use of mental-health language on social media contribute, increased awareness and reduced stigma encourage help-seeking and may inflate apparent rates, while genuine risk factors—economic insecurity, crises, and the after-effects of the pandemic—likely also play a role; a nuanced view recognizing multiple simultaneous factors is needed, and individuals’ distress must be believed and taken seriously.
Melanoma cases are increasing among women under 50, largely due to UV exposure from sun and indoor tanning, although overdiagnosis may also play a role; skin cancer remains the most common and deadly in the U.S.
The article discusses how the medical system's reliance on changing numerical thresholds for diagnoses like hypertension and kidney disease has led to widespread overdiagnosis and overtreatment, driven by broadening definitions and influenced by organizations, often without considering individual patient nuances or potential harms of aggressive treatment.
A 15-year trial on prostate cancer screening using the PSA blood test found that while it had a small impact on reducing deaths, it also led to a worrying level of overdiagnosis, with one in six flagged cases being wrong. The study showed that the potential harms of the test, including unnecessary treatment and physical side effects, outweigh the benefits. Experts emphasize the need to find better ways to detect aggressive prostate cancers and are exploring alternatives such as MRI scans. The UK National Screening Committee does not currently recommend screening for prostate cancer due to the unclear balance between benefits and harms.
The widespread use of therapy in America has raised concerns that it may be fueling the country's depression crisis by instilling a 'victim' mentality and fostering hyper-focus on feelings. The number of Americans seeking therapy has doubled in the past 20 years, with around a quarter of US adults visiting a therapist or psychiatrist in 2022. Experts worry that therapy may be overdiagnosing and overtreating everyday problems, leading to a paradox where more treatment availability does not correspond to a decrease in depression prevalence. There are concerns that therapy may be harming America's youth by encouraging excessive self-focus and reducing engagement with the world, potentially leading to a rise in mental health diagnoses and a lowering of the bar for mental illnesses.
A study suggests that over half of melanoma diagnoses in the U.S. may be unnecessary, particularly in White Americans, leading to unnecessary anxiety for patients. Increased awareness has led to more screenings and biopsies, but not necessarily a reduction in death rates. The study highlights the need for more precise diagnostic criteria and a reevaluation of how early-stage melanomas should be treated and communicated to patients.
Melanoma diagnoses have increased significantly in recent years, but experts believe that many of these cases are due to overdiagnosis rather than a true increase in the disease. A study suggests that a majority of people in the United States are receiving unnecessary melanoma diagnoses, leading to unnecessary treatments, financial costs, and emotional distress. Overdiagnosis is particularly common for thin moles on the outermost layer of the skin. There is a lack of scientific evidence supporting regular full-body skin checks, and experts recommend that individuals seek medical evaluation for any new or changing skin spots rather than undergoing routine screenings.